The objective is to meet the need of health care professionals for unbiased, reliable and timely information on new and older drugs, including the mechanisms of action, pharmacokinetics, clinical trials, adverse effects, interactions, dosages and routes of administration of the drugs discussed. The objectives will also meet the needs for unbiased, reliable and timely information on treatment of major diseases. Through this program, The Medical Letter expects to provide the prescribing health care community with educational content that they can use to make independent and informed therapeutic choices in their practice. Activity participants will read and assimilate unbiased reviews of FDA-approved and off-label uses of drugs and drug classes. Participants will be able to select and prescribe, or confirm the appropriateness of the prescribed usage of the drugs and other therapeutic modalities discussed, with specific attention to clinical evidence of effectiveness, adverse effects and patient management.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Address:
- 2 Madison Ave
Specialties served/covered
- Adolescent Medicine
- Cardiovascular Disease
- Critical Care Medicine
- Endocrinology, Diabetes & Metabolism
- General Internal Medicine
- General Surgery
- Geriatric Medicine
- Hematology
- Medical Oncology
- Nephrology
- Pulmonary Disease
- Rheumatology
- Cardio-Vascular
- Emergency & Critical Care
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Oncology & Hematology
- Primary care
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Included with subscription
Listed by the provider
- Enduring / On-demand
- Credit · Up to 2 credits
- MOC · Up to 2 points
- Included in subscription
-
ReleasedJan 8, 2026
-
Last day to claim creditJan 8, 2027 3 months left
-
Medical Letter, The 1743: Acetaminophen and Autism, PO Semaglutide for CV Risk, Insulins for Type 2 Diabetes
-
Medical Letter, The 1741: New Drugs for Presbyopia, UTI, and Hereditary Angioedema
-
Medical Letter, The 1748: A New Antibiotic, New Drugs for PAH, Hereditary Angioedema, Lymphoma and NSCLC, more
-
PACT Coalition for Safe and Drug-Free Communities +1 CME On-Demand PACT | Guidance to Practice: Applying CDC Recommendations for Effective Pain Management and Opioid Prescribing | Maureen Strohm, MD, FAAFP, DFASAM
-
CME Outfitters, LLC From Blueprint to Bedside: Implementing Opioid REMS for Patient-Centered Pain Management
-
Hartford HealthCare Safer Care in a Changing Drug Landscape: Detect, Support, Deprescribe (7th Annual Hartford HealthCare Opioid Symposium)
